Reported Earlier: Alps Group Rolling Out Internal Patient-Derived Organoid Program For Personalized Cancer Treatment In Partnership With Dr. Kong Wai Mun Of Axiocell Biotech
Benzinga Newsdesk 4 months ago
News
Alps Group Inc ("Alps" or "the Company") (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its expansion into patient-derived organoid (PDO) technology
Alps Group Inc ("Alps" or "the Company") (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development.